Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects

A Arashkia, S Jalilvand, N Mohajel… - Reviews in medical …, 2021 - Wiley Online Library
Summary Coronavirus disease 2019 (Covid‐19) is caused by severe acute respiratory
syndrome‐coronavirus‐2 (SARS‐CoV‐2) which is responsible for a global pandemic that …

Protective immunity against SARS subunit vaccine candidates based on spike protein: lessons for coronavirus vaccine development

A Khalaj-Hedayati - Journal of immunology research, 2020 - Wiley Online Library
The recent outbreak of the novel coronavirus disease, COVID‐19, has highlighted the threat
that highly pathogenic coronaviruses have on global health security and the imminent need …

Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development

SK Samrat, AM Tharappel, Z Li, H Li - Virus research, 2020 - Elsevier
The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern
to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are …

[HTML][HTML] SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies

AM Almehdi, G Khoder, AS Alchakee, AT Alsayyid… - Infection, 2021 - Springer
Purpose COVID-19 pandemic has emerged as a result of infection by the deadly pathogenic
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), causing enormous threats …

[HTML][HTML] The spike protein of SARS-CoV—a target for vaccine and therapeutic development

L Du, Y He, Y Zhou, S Liu, BJ Zheng… - Nature Reviews …, 2009 - nature.com
Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease caused
by a novel coronavirus, SARS-coronavirus (SARS-CoV). The SARS-CoV spike (S) protein is …

[HTML][HTML] Significance of conserved regions in coronavirus spike protein for developing a novel vaccine against SARS-CoV-2 infection

TA Olukitibi, Z Ao, B Warner, R Unat, D Kobasa, X Yao - Vaccines, 2023 - mdpi.com
Over the years, several distinct pathogenic coronaviruses have emerged, including the
pandemic SARS-CoV-2, which is difficult to curtail despite the availability of licensed …

[HTML][HTML] Stabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity

CM Zu Natrup, A Tscherne, C Dahlke… - The Journal of …, 2022 - Am Soc Clin Investig
The SARS-CoV-2 spike (S) glycoprotein is synthesized as a large precursor protein and
must be activated by proteolytic cleavage into S1 and S2. A recombinant modified vaccinia …

[HTML][HTML] Spike S2 subunit: the dark horse in the race for prophylactic and therapeutic interventions against SARS-CoV-2

KT Ng, NK Mohd-Ismail, YJ Tan - Vaccines, 2021 - mdpi.com
In the midst of the unceasing COVID-19 pandemic, the identification of immunogenic
epitopes in the SARS-CoV-2 spike (S) glycoprotein plays a vital role in the advancement …

[HTML][HTML] High-level expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably transfected CHO cells by the EEF1A1-based plasmid vector

MV Sinegubova, NA Orlova, SV Kovnir, LK Dayanova… - PLoS …, 2021 - journals.plos.org
The spike (S) protein is one of the three proteins forming the coronaviruses' viral envelope.
The S protein of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has …

Key mutations in the spike protein of SARS‐CoV‐2 affecting neutralization resistance and viral internalization

Q Wang, SB Ye, ZJ Zhou, AL Song… - Journal of Medical …, 2023 - Wiley Online Library
To control the ongoing COVID‐19 pandemic, a variety of severe acute respiratory syndrome
coronavirus 2 (SARS‐CoV‐2) vaccines have been developed. However, the rapid mutations …